Bichet D G, Razi M, Lonergan M, Arthus M F, Papukna V, Kortas C, Barjon J N
Service de Néphrologie, Hôpital du Sacré-Coeur de Montréal, PQ, Canada.
N Engl J Med. 1988 Apr 7;318(14):881-7. doi: 10.1056/NEJM198804073181403.
The antidiuretic hormone arginine vasopressin interacts with two types of receptors: V1, which mediates the effects of vasopressin on vascular smooth muscle, and V2, which mediates the antidiuretic effects on renal tubules. Resistance of the renal tubules to arginine vasopressin and to the antidiuretic V2-specific agonist 1-desamino[8-D-arginine] vasopressin (dDAVP) occurs in congenital nephrogenic diabetes insipidus, a rare X-linked disease, although the V1-receptor responses remain intact. The extrarenal actions of dDAVP in normal persons are a decrease in blood pressure, an increase in plasma renin activity, and stimulation of the release of factor VIIIc and von Willebrand factor. We measured the response of mean arterial pressure, pulse rate, plasma renin activity, factor VIIIc, and von Willebrand factor to an infusion of dDAVP (0.3 microgram per kilogram of body weight) in seven male patients with congenital nephrogenic diabetes insipidus, six obligatory carriers of the gene for nephrogenic diabetes insipidus, five patients with central diabetes insipidus, and four normal subjects. In the normal subjects and the patients with central diabetes insipidus, dDAVP decreased mean arterial pressure (by 10 to 15 percent) and increased pulse rate (by 20 to 25 percent), renin activity (by 65 percent), and the release of coagulation factors (twofold to threefold) (all changes were significant, P less than 0.01). None of these changes were observed in the patients with congenital nephrogenic diabetes insipidus, and minimal responses were observed in the obligatory carriers. These results confirm the existence of extrarenal vasopressin V2-like receptors, which may be defective in patients with congenital nephrogenic diabetes insipidus.
V1受体,介导加压素对血管平滑肌的作用;V2受体,介导对肾小管的抗利尿作用。先天性肾性尿崩症是一种罕见的X连锁疾病,肾小管对精氨酸加压素和抗利尿V2特异性激动剂1-去氨基[8-D-精氨酸]加压素(dDAVP)产生抵抗,尽管V1受体反应保持完整。dDAVP对正常人的肾外作用包括血压降低、血浆肾素活性增加以及刺激因子VIIIc和血管性血友病因子的释放。我们测量了7例先天性肾性尿崩症男性患者、6例肾性尿崩症基因的必然携带者、5例中枢性尿崩症患者和4名正常受试者在输注dDAVP(0.3微克/千克体重)后平均动脉压、脉率、血浆肾素活性、因子VIIIc和血管性血友病因子的反应。在正常受试者和中枢性尿崩症患者中,dDAVP使平均动脉压降低(10%至15%),脉率增加(20%至25%),肾素活性增加(65%),凝血因子释放增加(两倍至三倍)(所有变化均有统计学意义,P<0.01)。先天性肾性尿崩症患者未观察到这些变化,必然携带者观察到的反应最小。这些结果证实了肾外加压素V2样受体的存在,先天性肾性尿崩症患者的这些受体可能存在缺陷。